These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36233514)

  • 41. Is Timing of Steroid Exposure Prior to Immune Checkpoint Inhibitor Initiation Associated with Treatment Outcomes in Melanoma? A Population-Based Study.
    Nikita N; Banks J; Keith SW; Song A; Johnson JM; Wilson M; Sharma S; Lu-Yao G
    Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267602
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer.
    Chitturi KR; Xu J; Araujo-Gutierrez R; Bhimaraj A; Guha A; Hussain I; Kassi M; Bernicker EH; Trachtenberg BH
    JACC CardioOncol; 2019 Dec; 1(2):182-192. PubMed ID: 34396181
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival.
    Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M
    World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Multi-target combinatory strategy to overcome tumor immune escape.
    Yu Y
    Front Med; 2022 Apr; 16(2):208-215. PubMed ID: 35377102
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immune-checkpoint inhibitors in renal transplanted patients affected by melanoma: a systematic review.
    Rossi E; Schinzari G; Maiorano BA; Esposito I; Acampora A; Romagnoli J; Stefani AD; Regno LD; Lancellotta V; Fionda B; Tagliaferri L; Peris K; Tortora G
    Immunotherapy; 2022 Jan; 14(1):65-75. PubMed ID: 34751039
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment.
    Hurkmans DP; Verhoeven JGHP; de Leur K; Boer K; Joosse A; Baan CC; von der Thüsen JH; van Schaik RHN; Mathijssen RHJ; van der Veldt AAM; Hesselink DA
    J Immunother Cancer; 2019 Jul; 7(1):182. PubMed ID: 31300068
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Atypical Presentations and Management of Endocrine and Hepatic Immune-Related Adverse Events From Adjuvant Immune Checkpoint Inhibitor Therapy in Stage III Resected Melanoma.
    Kottschade LA; Yan Y
    JCO Oncol Pract; 2020 Feb; 16(2_suppl):10s-14s. PubMed ID: 32045536
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA.
    Kalinich M; Murphy W; Wongvibulsin S; Pahalyants V; Yu KH; Lu C; Wang F; Zubiri L; Naranbhai V; Gusev A; Kwatra SG; Reynolds KL; Semenov YR
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33789879
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Liver graft rejection following immune checkpoint inhibitors treatment: a review.
    Hu B; Yang XB; Sang XT
    Med Oncol; 2019 Oct; 36(11):94. PubMed ID: 31605245
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy.
    Halle BR; Betof Warner A; Zaman FY; Haydon A; Bhave P; Dewan AK; Ye F; Irlmeier R; Mehta P; Kurtansky NR; Lacouture ME; Hassel JC; Choi JS; Sosman JA; Chandra S; Otto TS; Sullivan R; Mooradian MJ; Chen ST; Dimitriou F; Long G; Carlino M; Menzies A; Johnson DB; Rotemberg VM
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34635495
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Risk of corticosteroid treatment and hospitalization after checkpoint inhibitor and radiation therapy in patients with cancer.
    Lee KE; Bender DA; Koutcher LD; Hyde B; Hur C; Faye AS; Cheng SK
    Cancer; 2022 Feb; 128(4):819-827. PubMed ID: 34634130
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
    Chen C; Wu B; Zhang C; Xu T
    Int Immunopharmacol; 2021 Jun; 95():107498. PubMed ID: 33725634
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ocular Adverse Events Induced by Immune Checkpoint Inhibitors: A Comprehensive Pharmacovigilance Analysis.
    Bomze D; Meirson T; Hasan Ali O; Goldman A; Flatz L; Habot-Wilner Z
    Ocul Immunol Inflamm; 2022 Jan; 30(1):191-197. PubMed ID: 32749899
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immune-Related Adverse Events After Immune Checkpoint Inhibitors for Melanoma Among Older Adults.
    Schonfeld SJ; Tucker MA; Engels EA; Dores GM; Sampson JN; Shiels MS; Chanock SJ; Morton LM
    JAMA Netw Open; 2022 Mar; 5(3):e223461. PubMed ID: 35315916
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States.
    Jain P; Gutierrez Bugarin J; Guha A; Jain C; Patil N; Shen T; Stanevich I; Nikore V; Margolin K; Ernstoff M; Velcheti V; Barnholtz-Sloan J; Dowlati A
    ESMO Open; 2021 Oct; 6(5):100252. PubMed ID: 34461483
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immune Checkpoint Inhibitors in Cancer Therapy.
    Shiravand Y; Khodadadi F; Kashani SMA; Hosseini-Fard SR; Hosseini S; Sadeghirad H; Ladwa R; O'Byrne K; Kulasinghe A
    Curr Oncol; 2022 Apr; 29(5):3044-3060. PubMed ID: 35621637
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review.
    Hao Y; Zhang X; Yu L
    Front Oncol; 2022; 12():911906. PubMed ID: 36052257
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Incidence, predictors and 6-month overall outcome of acute kidney injury in Chinese patients receiving PD-1 inhibitors.
    Qin Z; Liu K; Xu X; Li T; Ge Y; Wu B; Xing C; Mao H
    Future Oncol; 2022 May; 18(16):1951-1962. PubMed ID: 35232231
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
    Chu X; Zhao J; Zhou J; Zhou F; Jiang T; Jiang S; Sun X; You X; Wu F; Ren S; Zhou C; Su C
    Lung Cancer; 2020 Dec; 150():76-82. PubMed ID: 33080551
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events.
    Herrmann SM; Perazella MA
    Kidney Int Rep; 2020 Aug; 5(8):1139-1148. PubMed ID: 32775813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.